Oncternal Therapeutics, Inc. (ONCT): Price and Financial Metrics
ONCT Price/Volume Stats
| Current price | $8.00 | 52-week high | $13.14 |
| Prev. close | $8.25 | 52-week low | $5.57 |
| Day low | $8.00 | Volume | 406 |
| Day high | $8.00 | Avg. volume | 11,780 |
| 50-day MA | $8.84 | Dividend yield | N/A |
| 200-day MA | $7.78 | Market Cap | 21.51M |
ONCT Stock Price Chart Interactive Chart >
Oncternal Therapeutics, Inc. (ONCT) Company Bio
Oncternal Therapeutics (formerly GTx, Inc.), a biopharmaceutical company, engages in the discovery, development, and commercialization of small molecules for the treatment of breast and prostate cancer, and other serious medical conditions. The company was founded in 1997 and is based in Memphis, Tennessee.
Latest ONCT News From Around the Web
Below are the latest news stories about ONCTERNAL THERAPEUTICS INC that investors may wish to consider to help them evaluate ONCT as an investment opportunity.
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on TuesdayChecking out the biggest pre-market stock movers for Tuesday is the perfect way to get ready for another busy day of trading! |
Oncternal Therapeutics, Inc. (NASDAQ:ONCT) Q3 2023 Earnings Call TranscriptOncternal Therapeutics, Inc. (NASDAQ:ONCT) Q3 2023 Earnings Call Transcript November 9, 2023 Oncternal Therapeutics, Inc. misses on earnings expectations. Reported EPS is $-0.17 EPS, expectations were $-0.15. Operator: Greetings and welcome to Oncternal Therapeutics third-quarter 2023 financial results conference call. [Operator Instructions]. As a reminder, this conference is being recorded. I would now like to […] |
Oncternal Therapeutics Provides Business Update and Announces Third Quarter 2023 Financial ResultsThe first patient was dosed in our Phase 1/2 study for ONCT-534, our dual-action androgen receptor inhibitor, for the treatment of patients with advanced prostate cancer who are resistant to approved androgen receptor pathway inhibitorsAdditional patients were treated in our ongoing Phase 1/2 study for ONCT-808, our ROR1-targeting autologous CAR T cell therapy, for the treatment of patients with relapsed or refractory aggressive B-cell lymphoma, including patients that have failed prior CD19 CAR |
Oncternal Therapeutics to Provide Business Update and Report Third Quarter 2023 Financial ResultsSAN DIEGO, Nov. 02, 2023 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that it will report third quarter 2023 financial results after the U.S. financial markets close on Thursday, November 9, 2023. Oncternal’s management will host a webcast at 2:00 p.m. PT (5:00 p.m. ET) to provide a business update and discuss the Company’s third quarter financial results. The li |
Oncternal Therapeutics Announces FDA Granted Fast Track Designation for ONCT-534 for the Treatment of Metastatic Castration-Resistant Prostate CancerSAN DIEGO, Oct. 26, 2023 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that the U.S. Food and Drug Administration (FDA) has designated ONCT-534, its novel dual-acting androgen receptor inhibitor (DAARI), as a Fast Track development program for the investigation of the treatment of patients with relapsed or refractory metastatic castration-resistant prostate cancer |
ONCT Price Returns
| 1-mo | -2.44% |
| 3-mo | -11.31% |
| 6-mo | 25.00% |
| 1-year | 26.78% |
| 3-year | -93.75% |
| 5-year | -94.99% |
| YTD | -25.40% |
| 2023 | -46.38% |
| 2022 | -55.95% |
| 2021 | -53.67% |
| 2020 | 24.05% |
| 2019 | -27.66% |
Loading social stream, please wait...